Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$12.96 +0.12 (+0.93%)
At close: Oct 2, 2026 · 4:00 PM EDT

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2012 - 2024)

Updated

Enanta Pharmaceuticals (ENTA) posted Gains from Sales and Divestitures of -$6,000 for FY2025 (year ended Sep 30, 2025), compared with -$16,000 in FY2024.

Analysis

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2012 - 2024) Analysis & Trends

Since FY2011, Enanta Pharmaceuticals has reported Gains from Sales and Divestitures for 8 fiscal years.

  • The FY2025 figure stands as the highest annual Gains from Sales and Divestitures since FY2015.
  • Business Quant data shows ENTA's Gains from Sales and Divestitures at -$16,000 in FY2024 and -$150,000 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Enanta Pharmaceuticals 377.40 Mn -350.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -6,000.00
Sep 30, 2024 -16,000.00
Sep 30, 2023 -143,000.00
Sep 30, 2015 10,000.00
Jun 30, 2012 8,000.00
API Access

Enanta Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ENTA&period=max&api_key=YOUR_API_KEY